Iversen, LL. Consideration of the cathinones, Advisory Council on the Misuse of Drugs, 31 Mar 2010. 286 kB.
Gorceix, A; Jacquemin, C. Intérêt du pyrovalérone dans le traitement ambulatoire des états de fatigue (French). Ann. Méd.-Psychol., , 1970 (2), 624–632. 8.2 MB.
Deniker, P; Lôo, H; Cuche, H; Houx, JM. Utilisation abusive par les toxicomanes d’un psycho-stimulant, la pyrovalérone (French). Ann. Méd.-Psychol., 27 Oct 1975, 2 (4), 745–748. 5.2 MB.
Meltzer, PC; Butler, D; Deschamps, JR; Madras, BK. 1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors. J. Med. Chem., 23 Feb 2006, 49 (4), 1420–1432. 179 kB. https://doi.org/10.1021/jm050797a
Lancelot, JC; Robba, M; Bonnet, JJ; Vaugeois, JM; Costentin, J. Synthesis and preliminary study of the activity of thiophene analogues of pyrovalerone on the neuronal uptake of the monoamines. Eur. J. Med. Chem., 1 Apr 1992, 27 (3), 297–200. 305 kB. https://doi.org/10.1016/0223-5234(92)90015-S
Prosser, JM; Nelson, LS. The toxicology of bath salts: a review of synthetic cathinones. J. Med. Toxicol., 1 Nov 2011, 8 (1), 33–22. 267 kB. https://doi.org/10.1007/s13181-011-0193-z
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 1 Jan 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
Collins, M. Some new psychoactive substances: Precursor chemical and synthesis-driver end-products. Drug Test. Analysis, 1 Jul 2001, 3 (7–8), 404–416. 178 kB. https://doi.org/10.1002/dta.315
Fornal, E. Study of collision-induced dissociation of electrospray-generated protonated cathinones. Drug Test. Analysis, 1 Jul 2014, 6 (7-8), 705-715. 527 kB. https://doi.org/10.1002/dta.1573 #25
Mas-Morey, P; Visser, MHM; Winkelmolen, L; Touw, DJ. Clinical Toxicology and Management of Intoxications With Synthetic Cathinones ("Bath Salts"). J. Pharm. Pract., 25 Nov 2012, 26 (4), 353-357. 312 kB. https://doi.org/10.1177/0897190012465949
Rickli, A; Hoener, MC; Liechti, ME. Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones. Eur. Neuropsychopharmacol., 1 Mar 2015, 25 (3), 365–376. 1.6 MB. https://doi.org/10.1016/j.euroneuro.2014.12.012 #Pyrovalerone
Baumann, MH; Walters, HM; Niello, M; Sitte, HH. Neuropharmacology of synthetic cathinones. In New Psychoactive Substances : Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 113–142. 409 kB. https://doi.org/10.1007/164_2018_178 #Pyrovalerone
Luethi, D; Liechti, ME. Monoamine transporter and receptor interaction profiles in vitro predict reported human doses of novel psychoactive stimulants and psychedelics. Int. J. Neuropsychoph., 1 Oct 2018, 21 (10), 926–931. 254 kB. https://doi.org/10.1093/ijnp/pyy047 #S1 Cathinones Pyrovalerone
Kraemer, M; Boehmer, A; Madea, B; Maas, A. Death cases involving certain new psychoactive substances: A review of the literature. Forensic Sci. Int., 1 May 2019, 298 186–267. 6.7 MB. https://doi.org/10.1016/j.forsciint.2019.02.021 #Pyrovalerone
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #CA-010
· Isomer Design